Top Story Today
Vaxcyte's 31-Serotype Vaccine Just Crashed the Pneumococcal Party
Vaxcyte, a company with zero approved products, just proved its 31-serotype pneumococcal vaccine can match both Pfizer's Prevnar 20 and Merck's Capvaxive across shared serotypes in a pivotal Phase 3 trial. Then it pulled ahead on the serotypes the competitors can't even cover. VAX-31 pushes estimated coverage to roughly 88% of circulating pneumococcal pneumonia in U.S. adults over 50, and its safety profile looked clean. If vaccines were cable packages, Pfizer is offering a decent bundle while Vaxcyte just showed up with every channel, including the ones you didn't know existed. The $8-to-$10 billion pneumococcal market may never look the same.
Why it matters: A generational leap from 20 to 31 serotypes could capture an additional 12% to 40% of disease burden beyond current vaccines, threatening two decades of Pfizer and Merck dominance in one of pharma's most profitable markets.
Read more →Deals and Partnerships
Pharma's Most Famous Couple Just Renewed Their Vows for $8 Billion
Sanofi and Regeneron were literally suing each other last year. Now they've inked an $8 billion expansion covering four next-generation antibodies aimed at protecting the franchise Dupixent built ($17.8 billion in 2025 sales). Sanofi pays $1 billion upfront; the companies split costs and profits 50/50. The real motive: building successors before Dupixent's patent cliff arrives.
Read more →Genentech Pays $100M Upfront for a Brain Delivery Trick Worth $1.3B
Genentech licensed Alector's preclinical Parkinson's program AL050, paying $100 million upfront with up to $1.27 billion in milestones. The real prize: Alector's brain carrier platform, which hijacks the transferrin receptor to sneak drugs past the blood-brain barrier. For a stock trading under $2 before the announcement, the deal is a lifeline and a validation.
Read more →The Organ Everyone Forgot Is Now Worth $560 Million
Two-year-old startup Tolerance Bio inked its second major deal, licensing Tanabe's anti-IL-33 antibody in a package worth up to $560 million. The company's thesis: instead of suppressing the immune system after it goes haywire, retrain it at the source by targeting the thymus. Total deal value across partnerships now exceeds $800 million.
Read more →GE HealthCare Drops $945 Million on Radioactive Pizza Delivery
GE HealthCare is acquiring SOFIE Biosciences and its network of 15 facilities with 21 cyclotrons for $945 million in cash. The logic: PET tracers decay so fast that a missed delivery window means a useless dose. Owning the "final mile" manufacturing network could become the biggest competitive moat in radiopharmaceuticals.
Read more →Clinical and Regulatory
An RNA Drug Just Crashed Kidney Disease's Most Crowded Party
Roche and Ionis's antisense drug sefaxersen hit its primary endpoint in a Phase 3 interim analysis, significantly reducing protein leakage in IgA nephropathy patients. The catch: six drugs are already approved for the disease. Being seventh means proving you're not just good, but different enough to earn a spot on an increasingly crowded formulary.
Read more →The FDA Just Rewrote the ADC Playbook, and Dozens of Companies Missed the Memo
Daiichi Sankyo and Merck pulled their lung cancer ADC filing before the FDA decision date after the agency said their Phase 2 data wasn't enough. The signal is clear: single-arm trials are no longer the default ticket to accelerated approval. Any ADC sponsor without a confirmatory trial already enrolling should be nervous.
Read more →BridgeBio's Rare Disease Drug Is Fixing Hearts Nobody Knew Were Breaking
BridgeBio's BBP-418 didn't just hit all endpoints in its Phase 3 muscular dystrophy trial; it pushed cardiac biomarkers back to normal levels. Among treated patients with elevated troponin, 100% returned to the healthy range versus 40% on placebo. With an FDA decision date of November 27, this could become the first approved therapy for LGMD2I/R9.
Read more →Novo Nordisk's Hemophilia Drug Aced Its Trials. The Factory Didn't.
The FDA extended its review of Novo Nordisk's hemophilia A drug denecimig, and the reason has nothing to do with clinical data. Manufacturing facility issues flagged during a pre-license inspection are the holdup. Novo still targets a first-half 2027 launch, but every month of delay gives Roche's Hemlibra more time to entrench.
Read more →Industry and Funding
Nine Pharma CEOs Just Sent a 911 Call to Brussels
Chairs from Roche, Novo Nordisk, Sanofi, and six other pharma giants co-signed a letter warning that Europe captures a shrinking share of global health-biotech venture capital. Clinical trial approvals lag behind the U.S. The message to policymakers: treat pharma like strategic infrastructure, or watch the industry leave.
Read more →Enveda Raises $311M to Let Nature Do the Drug Design
Enveda Biosciences closed a $311 million Series E at a $2 billion valuation, betting that AI can decode the chemical library evolution has been building for 3.8 billion years. The company already has a clinical-stage program in atopic dermatitis, which puts it ahead of most AI drug discovery peers.
Read more →